GW Pharma Sativex proves beneficial in Phase II trial
Phase II clinical study was a double-blind, randomised, placebo-controlled, parallel-group trial designed to evaluate Sativex in patients with MS and overactive bladder (OAB) that was not responding adequately
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.